tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GYRE Stock Latest News

Regulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
RatingsRegulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
12d ago
GYRE
Gyre Therapeutics Advances Hydronidone Toward China Approval
PremiumCompany Announcements
Gyre Therapeutics Advances Hydronidone Toward China Approval
12d ago
8K
GYRE
Gyre Therapeutics announces alignment with China’s CDE on hydronidone
PremiumThe Fly
Gyre Therapeutics announces alignment with China’s CDE on hydronidone
12d ago
GYRE
Gyre Therapeutics Reports Strong Q3 2025 Results
PremiumCompany Announcements
Gyre Therapeutics Reports Strong Q3 2025 Results
2M ago
GYRE
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
PremiumRatings
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
2M ago
GYRE
Gyre Therapeutics cuts FY25 revenue view to $115M-$118M from $118M-$128M
PremiumThe FlyGyre Therapeutics cuts FY25 revenue view to $115M-$118M from $118M-$128M
2M ago
GYRE
Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
Premium
The Fly
Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
2M ago
GYRE
Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
Premium
Ratings
Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
3M ago
GYRE
Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
PremiumThe Fly
Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
3M ago
GYRE
Gyre Therapeutics initiated with a Buy at Jefferies
PremiumThe Fly
Gyre Therapeutics initiated with a Buy at Jefferies
3M ago
GYRE
Gyre Therapeutics Announces Positive Phase 3 Results
PremiumCompany Announcements
Gyre Therapeutics Announces Positive Phase 3 Results
4M ago
8K
GYRE
Gyre Therapeutics: A Compelling Buy with Potential Blockbuster Drug Hydronidone Targeting Liver Fibrosis
PremiumRatings
Gyre Therapeutics: A Compelling Buy with Potential Blockbuster Drug Hydronidone Targeting Liver Fibrosis
5M ago
GYRE
Gyre Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyGyre Therapeutics initiated with a Buy at H.C. Wainwright
5M ago
GYRE
Gyre Therapeutics Appoints Dan Weng to Board
Premium
Company Announcements
Gyre Therapeutics Appoints Dan Weng to Board
5M ago
8K
GYRE
Gyre Therapeutics appoints Dan Weng to board of directors
Premium
The Fly
Gyre Therapeutics appoints Dan Weng to board of directors
5M ago
GYRE
Gyre Therapeutics Reports Q2 2025 Earnings and Strategic Updates
PremiumCompany Announcements
Gyre Therapeutics Reports Q2 2025 Earnings and Strategic Updates
5M ago
GYRE
Gyre Therapeutics Appoints Ping Zhang as Interim CEO
PremiumCompany Announcements
Gyre Therapeutics Appoints Ping Zhang as Interim CEO
5M ago
8K
GYRE
Gyre Therapeutics CEO Han Ying steps down
PremiumThe Fly
Gyre Therapeutics CEO Han Ying steps down
5M ago
GYRE
Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success
PremiumRatings
Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success
7M ago
GYRE
Gyre Therapeutics announces first doing in Phase 1 trial of F230
PremiumThe FlyGyre Therapeutics announces first doing in Phase 1 trial of F230
7M ago
GYRE
Gyre Therapeutics Holds 2025 Annual Stockholders Meeting
Premium
Company Announcements
Gyre Therapeutics Holds 2025 Annual Stockholders Meeting
8M ago
8K
GYRE
Gyre Therapeutics Announces Stock Offering Agreement
Premium
Company Announcements
Gyre Therapeutics Announces Stock Offering Agreement
8M ago
8K
GYRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >